{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:33:58Z","timestamp":1793111638008,"version":"4.5.0"},"reference-count":62,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jtim-2025-0028_s_006\">\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>Relapse is one of the most critical causes of transplant failure in patients with acute myeloid leukemia (AML) receiving haploidentical-related donor (HID) hematopoietic stem cell transplantation (HSCT). We aimed to develop an artificial intelligence (AI)-based predictive model for post-transplant relapse in patients with AML receiving HID HSCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jtim-2025-0028_s_007\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study included patients with consecutive AML (aged \u2265 12 years) receiving HID HSCT in complete remission (CR). We randomly selected 70% of the entire population (\n                      <jats:italic>n<\/jats:italic>\n                      = 665) as the training cohort for developing the model and nomogram, which were both evaluated using data from the remaining 30% of the patients (validation cohort,\n                      <jats:italic>n<\/jats:italic>\n                      = 286). Furthermore, the model was validated in an independent cohort (\n                      <jats:italic>n<\/jats:italic>\n                      = 213) and in the clinical practice of five experienced clinicians.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jtim-2025-0028_s_008\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Five variables (AML risk category, number of courses of induction chemotherapy for first CR, disease status, measurable residual disease before HSCT, and blood group disparity) were included in the final model (\n                      <jats:italic>i.e<\/jats:italic>\n                      ., PKU-AML model). The concordance index of the nomogram was 0.707. The Hosmer\u2212Lemeshow test showed a good fit for this model (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.205). The calibration curve was close to the ideal diagonal line, and decision curve analysis showed a significantly better net benefit for this model. The reliability of our prediction nomogram was demonstrated in a validation cohort, an independent cohort, and in clinical practice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jtim-2025-0028_s_0009\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our PKU-AML model can predict the relapse of patients with AML receiving HID HSCT in CR, providing an effective tool for the early prediction and timely management of post-transplant relapse.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jtim-2025-0028","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T08:57:19Z","timestamp":1750409839000},"page":"253-266","source":"Crossref","is-referenced-by-count":19,"title":["Artificial intelligence-based predictive model for relapse in acute myeloid leukemia patients following haploidentical hematopoietic cell transplantation"],"prefix":"10.1515","volume":"13","author":[{"given":"Shuang","family":"Fan","sequence":"first","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyang","family":"Hong","sequence":"additional","affiliation":[{"name":"National Institute of Health Data Science, Peking University , Beijing , China"},{"name":"Institute of Medical Technology, Peking University Health Science Center , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengye","family":"Lu","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wen","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenda","family":"Hong","sequence":"additional","affiliation":[{"name":"National Institute of Health Data Science, Peking University , Beijing , China"},{"name":"Institute of Medical Technology, Peking University Health Science Center , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanping","family":"Xu","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhua","family":"Yan","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Chen","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Chen","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengrong","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingzhi","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing , China"},{"name":"Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University , Beijing , China"},{"name":"Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies (2019RU029), Chinese Academy of Medical Sciences , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Mo","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing , China"},{"name":"Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies (2019RU029), Chinese Academy of Medical Sciences , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"2025062613593418070_j_jtim-2025-0028_ref_001","doi-asserted-by":"crossref","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev 2019;36:70\u201387.","DOI":"10.1016\/j.blre.2019.04.005"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_002","doi-asserted-by":"crossref","unstructured":"Lv M, Shen M, Mo X. Development of allogeneic hematopoietic stem cell transplantation in 2022: Regenerating \"Groot\" to heal the world. Innovation (Camb) 2023;4:100373.","DOI":"10.1016\/j.xinn.2023.100373"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_003","doi-asserted-by":"crossref","unstructured":"Lv M, Gorin NC, Huang XJ. A vision for the future of allogeneic hemat-opoietic stem cell transplantation in the next decade. Sci Bull (Beijing) 2022;67:1921\u20131924.","DOI":"10.1016\/j.scib.2022.09.004"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_004","doi-asserted-by":"crossref","unstructured":"Wang L, Zhang C, Fan S, Mo X, Hu X. Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy?Innovation (Camb) 2023;4:100461.","DOI":"10.1016\/j.xinn.2023.100461"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_005","doi-asserted-by":"crossref","unstructured":"Cao Y, Zhang C, Cao L, Mo X, Hu X. Quizartinib is a good option for AML patients with FLT3-ITD mutations. TIME 2023;1:100007.","DOI":"10.59717\/j.xinn-med.2023.100007"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_006","doi-asserted-by":"crossref","unstructured":"Xu LP, Lu DP, Wu DP, Jiang EL, Liu DH, Huang H, et al. Hematopoietic Stem Cell Transplantation Activity in China 2020-2021 During the SARS-CoV-2 Pandemic: A Report From the Chinese Blood and Marrow Transplantation Registry Group. Transplant Cell Ther 2023;29:136.","DOI":"10.1016\/j.jtct.2022.11.011"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_007","doi-asserted-by":"crossref","unstructured":"Xu LP, Lu PH, Wu DP, Sun ZM, Liu QF, Han MZ, et al. Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group. Bone Marrow Transplant 2021;56:2940\u20132947.","DOI":"10.1038\/s41409-021-01431-6"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_008","doi-asserted-by":"crossref","unstructured":"Lv M, Wang Y, Chang YJ, Zhang XH, Xu LP, Jiang Q, et al. Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission. Clin Cancer Res 2019;25:1737\u20131748.","DOI":"10.1158\/1078-0432.CCR-18-1637"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_009","doi-asserted-by":"crossref","unstructured":"Huang XJ, Zhu HH, Chang YJ, Xu LP, Liu DH, Zhang XH, et al. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood 2012;119:5584\u20135590.","DOI":"10.1182\/blood-2011-11-389809"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_010","doi-asserted-by":"crossref","unstructured":"Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood 2015;125:3956\u20133962.","DOI":"10.1182\/blood-2015-02-627786"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_011","doi-asserted-by":"crossref","unstructured":"Sanz J, Galimard JE, Labopin M, Afanasyev B, Angelucci E, Ciceri F, et al. Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. J Hematol Oncol 2020;13:46.","DOI":"10.1186\/s13045-020-00882-6"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_012","doi-asserted-by":"crossref","unstructured":"Yu S, Huang F, Wang Y, Xu Y, Yang T, Fan Z, et al. Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. Leukemia 2020;34:1433\u20131443.","DOI":"10.1038\/s41375-019-0686-3"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_013","doi-asserted-by":"crossref","unstructured":"Zheng FM, Zhang X, Li CF, Cheng YF, Gao L, He YL, et al. Haploidentical- versus identical-sibling transplant for high-risk pediatric AML: A multi-center study. Cancer Commun (Lond) 2020;40:93\u2013104.","DOI":"10.1002\/cac2.12014"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_014","doi-asserted-by":"crossref","unstructured":"Guo H, Chang YJ, Hong Y, Xu LP, Wang Y, Zhang XH, et al. Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. Cell Mol Immunol 2021;18:1172\u20131185.","DOI":"10.1038\/s41423-020-00597-1"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_015","doi-asserted-by":"crossref","unstructured":"Yan CH, Xu LP, Wang FR, Chen H, Han W, Wang Y, et al. Causes of mortality after haploidentical hematopoietic stem cell transplantation and the comparison with HLA-identical sibling hematopoietic stem cell transplantation. Bone Marrow Transplant 2016;51:391\u2013397.","DOI":"10.1038\/bmt.2015.306"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_016","doi-asserted-by":"crossref","unstructured":"Mo XD, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, et al. Disease risk comorbidity index for patients receiving haploidentical allogeneic hematopoietic transplantation. Engineering 2021;7(2):162-9.","DOI":"10.1016\/j.eng.2020.12.005"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_017","doi-asserted-by":"crossref","unstructured":"Zhao XS, Qin YZ, Liu YR, Chang YJ, Xu LP, Zhang XH, et al. The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission. Leuk Lymphoma 2017;58:1135\u20131143.","DOI":"10.1080\/10428194.2016.1239264"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_018","doi-asserted-by":"crossref","unstructured":"Liu J, Zhao XS, Liu YR, Xu LP, Zhang XH, Chen H, et al. Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Chin Med J (Engl) 2018;131:2808\u20132816.","DOI":"10.4103\/0366-6999.246072"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_019","doi-asserted-by":"crossref","unstructured":"Cao Y, Huo W, Huang J, Yang Y, Wang Y, Chang Y, et al. MRD positivity was the poor prognostic factor for adverse-risk AML patients with allogeneic hematopoietic stem cell transplantation: a multicenter TROPHY study. Blood Cancer J 2024;14:8.","DOI":"10.1038\/s41408-024-00976-1"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_020","doi-asserted-by":"crossref","unstructured":"Zhao X, Wang Z, Ruan G, Liu Y, Wang Y, Zhang X, et al. Impact of pretransplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation. Ann Hematol 2018;97:967\u2013975.","DOI":"10.1007\/s00277-018-3265-1"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_021","doi-asserted-by":"crossref","unstructured":"Chang YJ, Wang Y, Liu YR, Xu LP, Zhang XH, Chen H, et al. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol 2017;10:134.","DOI":"10.1186\/s13045-017-0502-3"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_022","doi-asserted-by":"crossref","unstructured":"Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, et al. Haploidentical transplantation for acute myeloid leukemia patients with minimal\/measurable residual disease at transplantation. Am J Hematol 2019;94:1382\u20131387.","DOI":"10.1002\/ajh.25647"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_023","doi-asserted-by":"crossref","unstructured":"Wang Y, Liu DH, Liu KY, Xu LP, Zhang XH, Han W, et al. Impact of pretransplantation risk factors on post transplantation outcome of patients with acute myeloid leukemia in remission after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013;19:283\u2013290.","DOI":"10.1016\/j.bbmt.2012.10.002"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_024","doi-asserted-by":"crossref","unstructured":"Piemontese S, Boumendil A, Labopin M, Schmid C, Ciceri F, Arcese W, et al. Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT. J Hematol Oncol 2019;12:68.","DOI":"10.1186\/s13045-019-0751-4"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_025","doi-asserted-by":"crossref","unstructured":"Chang YJ, Wang HT, Xu LP, Wang Y, Liu KY, Zhang XH, et al. Combined model of the EBMT score modified model and the HCT-CI improves the stratification of high-risk patients undergoing unmanipulated haploidentical blood and marrow transplantation. Leuk Lymphoma 2016;57:2133\u20132139.","DOI":"10.3109\/10428194.2015.1124990"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_026","doi-asserted-by":"crossref","unstructured":"Wang HT, Chang YJ, Xu LP, Liu DH, Wang Y, Liu KY, et al. EBMT risk score can predict the outcome of leukaemia after unmanipulated haploidentical blood and marrow transplantation. Bone Marrow Transplant 2014;49:927\u2013933.","DOI":"10.1038\/bmt.2014.80"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_027","doi-asserted-by":"crossref","unstructured":"Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 2014;123:3664\u20133671.","DOI":"10.1182\/blood-2014-01-552984"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_028","doi-asserted-by":"crossref","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912\u20132919.","DOI":"10.1182\/blood-2005-05-2004"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_029","doi-asserted-by":"crossref","unstructured":"Bejanyan N, Brunstein CG, Cao Q, Lazaryan A, Ustun C, Warlick ED, et al. Predictive value of disease risk comorbidity index for overall survival after allogeneic hematopoietic transplantation. Blood Adv 2019;3:230\u2013236.","DOI":"10.1182\/bloodadvances.2018018549"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_030","doi-asserted-by":"crossref","unstructured":"Kongtim P, Parmar S, Milton DR, Perez JMR, Rondon G, Chen J, et al. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 2019;54:839\u2013848.","DOI":"10.1038\/s41409-018-0344-9"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_031","doi-asserted-by":"crossref","unstructured":"McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bola\u00f1os-Meade J, Rosner GL, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 2015;125:3024\u20133031.","DOI":"10.1182\/blood-2015-01-623991"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_032","doi-asserted-by":"crossref","unstructured":"Mo XD, Xu LP, Liu DH, Zhang XH, Chen H, Chen YH, et al. The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) is an outcome predictor for partially matched related donor transplantation. Am J Hematol 2013;88:497\u2013502.","DOI":"10.1002\/ajh.23443"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_033","doi-asserted-by":"crossref","unstructured":"Kongtim P, Hasan O, Perez JMR, Varma A, Wang SA, Patel KP, et al. Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2020;26:197\u2013203.","DOI":"10.1016\/j.bbmt.2019.09.006"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_034","doi-asserted-by":"crossref","unstructured":"Wang Y, Liu QF, Lin R, Yang T, Xu YJ, Mo XD, et al. Optimizing antithy-mocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial. Sci Bull (Beijing) 2021;66:2498\u20132505.","DOI":"10.1016\/j.scib.2021.06.002"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_035","doi-asserted-by":"crossref","unstructured":"Mo XD, Hong SD, Zhao YL, Jiang EL, Chen J, Xu Y, et al. Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis. Am J Hematol 2022;97:458\u2013469.","DOI":"10.1002\/ajh.26475"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_036","doi-asserted-by":"crossref","unstructured":"Shen MZ, Hong SD, Lou R, Chen RZ, Zhang XH, Xu LP, et al. A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation. Exp Hematol Oncol 2022;11:25.","DOI":"10.1186\/s40164-022-00278-x"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_037","doi-asserted-by":"crossref","unstructured":"Fan S, Hong HY, Dong XY, Xu LP, Zhang XH, Wang Y, et al. Machine learning algorithm as a prognostic tool for Epstein-Barr virus reactivation after haploidentical hematopoietic stem cell transplantation. Blood Sci 2022;5:51\u201359.","DOI":"10.1097\/BS9.0000000000000143"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_038","doi-asserted-by":"crossref","unstructured":"Deng DX, Shen MZ, Zhang XH, Xu L, Wang Y, Yan CH, et al. P1292: Basiliximab may be the potential solution for severe liver chronic graft-versus-host disease: A prospective pilot study. HemaSphere 2023;7.","DOI":"10.1097\/01.HS9.0000972056.91461.24"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_039","doi-asserted-by":"crossref","unstructured":"Xu Z, Mo X, Kong Y, Wen Q, Han T, Lyu M, et al. Mini-dose metho-trexate combined with methylprednisolone as a first-line treatment for acute graft-versus-host disease: A phase 2 trial. J Transl Int Med 2023;11:255\u2013264.","DOI":"10.2478\/jtim-2023-0111"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_040","doi-asserted-by":"crossref","unstructured":"Deng D, Shen M, Zhang X, Xu L, Wang Y, Yan C, et al. Basiliximab is the potential solution for severe liver chronic GVHD: A prospective pilot study. TIME 2023;1:100009.","DOI":"10.59717\/j.xinn-med.2023.100009"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_041","doi-asserted-by":"crossref","unstructured":"Mo XD, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, et al. Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia\/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes. Eur J Haematol 2016;96:297\u2013308.","DOI":"10.1111\/ejh.12591"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_042","doi-asserted-by":"crossref","unstructured":"Shen MZ, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, et al. Preemptive Interferon-\u03b1 Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies. Front Immunol 2022;13:757002.","DOI":"10.3389\/fimmu.2022.757002"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_043","unstructured":"Yang D. Build prognostic nomograms for risk assessment using SAS. Paper presented at: SAS Global Forum 2013; April 28-May 1, 2013; San Francisco, CA. Accessed 2024-09-24. Available from: https:\/\/support.sas.com\/resources\/papers\/proceedings13\/264-2013.pdf."},{"key":"2025062613593418070_j_jtim-2025-0028_ref_044","doi-asserted-by":"crossref","unstructured":"Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol 2015;16:e173\u2013180.","DOI":"10.1016\/S1470-2045(14)71116-7"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_045","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022;140:1345\u20131377.","DOI":"10.1182\/blood.2022016867"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_046","doi-asserted-by":"crossref","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695\u2013706.","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_047","doi-asserted-by":"crossref","unstructured":"Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol 2014;32:3249\u20133256.","DOI":"10.1200\/JCO.2013.53.8157"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_048","doi-asserted-by":"crossref","unstructured":"Jentzsch M, Bischof L, Backhaus D, Brauer D, Schulz J, Franke GN, et al. Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission. Blood Adv 2022;6:4570\u20134580.","DOI":"10.1182\/bloodadvances.2022007168"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_049","doi-asserted-by":"crossref","unstructured":"Mo XD, Lv M, Huang XJ. Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention. Br J Haematol 2017;179:184\u2013197.","DOI":"10.1111\/bjh.14778"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_050","doi-asserted-by":"crossref","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2021;138:2753\u20132767.","DOI":"10.1182\/blood.2021013626"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_051","doi-asserted-by":"crossref","unstructured":"Cai Z, Fan S, Sun X, Mo X, Yang G. Novel microfluidic device for measurable residual disease detection in acute leukemia. Innovation (Camb) 2023;4:100408.","DOI":"10.1016\/j.xinn.2023.100408"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_052","doi-asserted-by":"crossref","unstructured":"Liu J, Ma R, Liu YR, Xu LP, Zhang XH, Chen H, et al. The significance of peri-transplantation minimal residual disease assessed by multiparameter flow cytometry on outcomes for adult AML patients receiving haploidentical allografts. Bone Marrow Transplant 2019;54:567\u2013577.","DOI":"10.1038\/s41409-018-0300-8"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_053","doi-asserted-by":"crossref","unstructured":"Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol 2020;21:1201\u20131212.","DOI":"10.1016\/S1470-2045(20)30455-1"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_054","doi-asserted-by":"crossref","unstructured":"Li Z, Shi W, Lu X, Lu H, Cao X, Tang L, et al. Decitabine-Intensified Modified Busulfan\/Cyclophosphamide Conditioning Regimen Improves Survival in Acute Myeloid Leukemia Patients Undergoing Related Donor Hematopoietic Stem Cell Transplantation: A Propensity Score Matched Analysis. Front Oncol 2022;12:844937.","DOI":"10.3389\/fonc.2022.844937"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_055","doi-asserted-by":"crossref","unstructured":"Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Zhang XH, et al. Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched\/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis. Bone Marrow Transplant 2012;47:1099\u20131104.","DOI":"10.1038\/bmt.2011.213"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_056","doi-asserted-by":"crossref","unstructured":"Wang Y, Liu QF, Wu DP, Wang JB, Zhang X, Wang HX, et al. Impact of prophylactic\/preemptive donor lymphocyte infusion and intensified conditioning for relapsed\/refractory leukemia: a real-world study. Sci China Life Sci 2020;63:1552\u20131564.","DOI":"10.1007\/s11427-019-1610-2"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_057","doi-asserted-by":"crossref","unstructured":"Yan CH, Wang Y, Sun YQ, Cheng YF, Mo XD, Wang FR, et al. Optimized therapeutic strategy for patients with refractory or relapsed acute myeloid leukemia: long-term clinical outcomes and health-related quality of life assessment. Cancer Commun (Lond) 2022;42:1387\u20131402.","DOI":"10.1002\/cac2.12376"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_058","doi-asserted-by":"crossref","unstructured":"Kungwankiattichai S, Ponvilawan B, Roy C, Tunsing P, Kuchenbauer F, Owattanapanich W. Maintenance With Hypomethylating Agents After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2022;9:801632","DOI":"10.3389\/fmed.2022.801632"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_059","doi-asserted-by":"crossref","unstructured":"Gao L, Zhang Y, Wang S, Kong P, Su Y, Hu J, et al. Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial. J Clin Oncol 2020;38:4249\u20134259.","DOI":"10.1200\/JCO.19.03277"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_060","doi-asserted-by":"crossref","unstructured":"Lund TC, Ahn KW, Tecca HR, Hilgers MV, Abdel-Azim H, Abraham A, et al. Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. Biol Blood Marrow Transplant 2019;25:301\u2013306.","DOI":"10.1016\/j.bbmt.2018.09.016"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_061","doi-asserted-by":"crossref","unstructured":"Ji GW, Zhu FP, Xu Q, Wang K, Wu MY, Tang WW, et al. Machine-learning analysis of contrast-enhanced CT radiomics predicts recurrence of hepatocellular carcinoma after resection: A multi-institutional study. EBioMedicine 2019;50:156\u2013165.","DOI":"10.1016\/j.ebiom.2019.10.057"},{"key":"2025062613593418070_j_jtim-2025-0028_ref_062","doi-asserted-by":"crossref","unstructured":"Chu CS, Lee NP, Adeoye J, Thomson P, Choi SW. Machine learning and treatment outcome prediction for oral cancer. J Oral Pathol Med 2020;49:977\u2013985.","DOI":"10.1111\/jop.13089"}],"container-title":["Journal of Translational Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2025-0028\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2025-0028\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T10:00:12Z","timestamp":1750932012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2025-0028\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":62,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,6,20]]},"published-print":{"date-parts":[[2025,6,26]]}},"alternative-id":["10.1515\/jtim-2025-0028"],"URL":"https:\/\/doi.org\/10.1515\/jtim-2025-0028","relation":{},"ISSN":["2224-4018"],"issn-type":[{"value":"2224-4018","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}